HONG KONG, July 31, 2014 /PRNewswire/ -- China Cord
Blood Corporation (NYSE: CO) ("CCBC" or the "Company"),
China's leading provider of cord
blood collection, laboratory testing, hematopoietic stem cell
processing, and stem cell storage services, today announced that
the Company has filed with the U.S. Securities and Exchange
Commission its Annual Report on Form 20-F, which included audited
financial statements for the fiscal year ended March 31, 2014. The Form 20-F can be accessed by
visiting the U.S. Securities and Exchange Commission's website at
http://www.sec.gov and also be found at the Investor Relations
section of CCBC's website at http://ir.chinacordbloodcorp.com. CCBC
will provide a hard copy of the Annual Report, including a complete
set of audited financial statements, free of charge to its
shareholders upon request.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical
cord blood banking operator in China in terms of geographical coverage and
the only cord blood banking operator with multiple licenses. Under
current PRC government regulations, only one licensed cord blood
banking operator is permitted to operate in each licensed region
and only seven licenses have been authorized as of
today. China Cord Blood Corporation provides cord blood
collection, laboratory testing, hematopoietic stem cell processing,
and stem cell storage services. For more information, please visit
our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, performance and
results of operations, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
contained in statements filed from time to time with the U.S.
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the Company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the Company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
Mr. Bill Zima
Tel: (+86) 10-6583-7511 (China) or
(+1) 646-405-5185 (U.S.)
Email: william.zima@icrinc.com
SOURCE China Cord Blood Corporation